This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

hi guys... with MMG from 300p, looking forwards 220p in short futher.. any chance? thanks
swseun

AGM is due end of the month so DB will update us on the latest Glaxo rumour.

Cheers lads. Im just supping my stella. By the way the PM was nothing re- to MMG.

From the other place. The next 12 months are going to be interesting. If you fancy a blue sky stock then this is the one. A cure for cancer, what's that worth, billions. Any news of a tie up and this will rocket, but patience will be needed and rewarded. LOL

M25 - 20 Sep'06 - 22:54 - 7705 of 7712


AGM Update -
A few of my observations.
DB stated that all 3 technologies continue to show positive indications and a point he reiterated more than once throughout his presentation was that if there were any bad news, it would be disclosed immediately.
He stated that with the 3 technology platforms, there were effectively 3 chances of hitting the jackpot.
Now the nitty gritty.

Genvax
(Intersting to note DNA vaccines appears 1st in order in MMI AGM Report).

Further patents have been granted on their Lung and colon cancers. (No RNS needed as there are so many patents already).
2 new scientists have been appointed to assist with the tuberculosis vaccine and I got the impression DB rather likes this one as he mentioned it several times throughout his speech.
The Lymphoma vaccine was mentioned in that the market had grown rapidly to be worth 3bn currently.
MMI are in talks with a US co(emphasised because that is the key market for the vaccine). I also got the impression the progression to PIIb would be with a partner.
Prostate PIIa trial results expected before year end.
Because of the regulatory framework, MMI is unable to show shareholders preliminary results which was mentioned a few times in the Q&A by Michael Walters I believe.

Oncosense
8 week setback with Ru trial start due to impurities.
Now expected to commense Jan 07.
Stability testing is ongoing and has so far proved ok.
The 3rd Ru compound (4414) has been dropped in favour of 4417 due to complicated and expensive manufacturing process.
2nd generation Ru drugs being developed using computers to optimise efficacy.
A question was raised against this statement which was cleverly fielded by Dr James Brenton in that Cisplatin first entered clinical tials in the 1970s. It is still in trials today used in conjunction with other therapies due to its good properties.

Viratis
Lots of progress but still a long way from clinic and adding real value so nothing much to report.

Overall
David was non-commital when pressed about partnerships etc.
When pushed on a question, "Could you have had a deal by now if you had wanted" was met by a reluctant yes (said with a glance towards the advisors).
Same chap also asked if the shareholders would have a good Xmas. David said that he planned to (with his family).
DB was quite jovial and relaxed which to me indicates his strong position and he also added several non top 10 pharmas had joined the table, although which table he did not say.
He described them as special situations.

Can see less reason to sell now than yesterday but then i don't day trade these.



BennytheBall - 20 Sep'06 - 23:02 - 7706 of 7712


Feedback, yes. After the formal bit of the meeting (all resolutions passed), there was a presentation by David Best and then Q&As with DB and the board.

The presentation elaborated on the content of the 'Latest Portfolio Developments' RNS this morning, drawing out a few interesting themes such as
- H5N1 (and HPV) vaccine developments, misleading spin and MMI's strong position in the industry
- Viratis' sudden acceleration through the invention of a successful delivery mechanism
- details of a 6 week delay in the Ruthenium trial programme
- Genvax retaining their focus on lucrative bespoke vaccines, at the same time as developing tumour-type specific and now broad range cancer vaccines
- Data from 1st generation Genvax trials (bespoke vaccines) complete and now being analysed [presumably formal confirmation of what we've been excited about since March 2005]
- Commencement of Ruthenium phase II trials to follow on the successful outcome of a research ethics committee submission in January 2007
- I'm sure there were one or two other striking points, but I can't be arsed to find my notes, as I'm knackered. Others can fill in.

In the Q&A bit, despite all of our efforts to draw David Best on the timing of the coming news of developments in the science or commercialisation, he remained calm, contained and professional.

He assured us that
- all was on track
- there had been dialogue with more than nine pharmas (but only nine of the biggest ten)
- we are more likely to glean there has been clinical progress through RNSs about deals than through RNSs about clinical progress, since MMI can share incomplete/pre-audited clinical data under NDAs with commercial partners ('insiders') that would not be releasable as RNSs for research ethics reasons, and such incomplete/pre-audited data is likely to drive deals
- a deal rather than clinical milestones may thus be the next thing to drive the price
- a deal could probably have been done by now if the board had not wanted to maximise the long term value of the company
- some of the interest from pharmas may have been driven by wanting to kill the competition rather than develop the product
- no news is good news - it means long-winded trials are progressing without any of the sequentially-recruited patients getting worse, and MMI continue to anticipate deals at the point where the deal value is optimised by research progress
- we can look forward to Christmas

;-)

I'd be interested to hear of any conversations with DB or board members I missed after leaving in a hurry at the end.

Ben

so where is MMG going to now? anyone?

A nice little 4% today. GF you still in?

MS

Sorry 5%.Opps

MS

nice to see it up.. will it last long? fly over 300p? or practice its up and down again??

At DB's last meeting in Sept I think it was, he said he expects to increase shareholder value significantly this year. If they sign a deal with one of the big boys then this will fly way past 3. Be patient and hold your nerve.

LOL
MS

Thanks mickeyskint,
I guess it will happen in last Nov.. just pure guess.. coz MMG always move slow.
Wish it is not too late to top up next monday (coz friday 13th is not my day) !! :-)

Good day to day. Mickey is Evil still in these?, Id ring him but last I heard I think hes gone on a piss up to Norfolk as he usually does this time of year on his birthday.

Moving up.

GF

Yes he is still in. When they get a deal with one of the big boys thses will fly. I think there is only 50 mil shares in issue and DB holds a fair chunk. The next 12 months will be very interesting.

LOL
MS

Fingers crossed.

Medical Marketing Int'l Group PLC
17 October 2006



Notification of Major Interests in Shares

October 17th 2006. Medical Marketing International Group plc ('Company') (AIM:
MMG) the UK virtual pharmaceutical development company focused on drugs for the
treatment of cancer and infectious diseases, received notification on 16th
October 2006 that Man Financial Limited is the beneficial owner of 2,331,700
ordinary shares of 0.2p in the Company representing 3.98% of the issued share
capital of the Company.


-ends-


Contacts

Medical Marketing International Group plc Brunswick Group LLP
David Best Justine McIlroy / Alex Tweed /
Executive Chairman Jon Coles
Tel. +44 (0) 207 404 5959
Rob Sprawson
Chief Financial Officer

Tel: +44 (0) 1223 477 677


About MMI Group

MMI is a virtual pharmaceutical development company that identifies, acquires
and develops world-class compounds and technologies from leading academic
organizations. These technologies are aimed at producing blockbuster drugs to
satisfy unmet needs in major therapeutic markets. The company manages the
preclinical and early clinical development of drug candidates before pursuing
licensing partners to manage late-stage development. Through its three platform
technologies MMI has a risk-balanced portfolio of compounds in development for
the treatment of cancer and infectious disease. Please visit

That made the share price value drop, isn't it?

from the other site:

Inovio Biomedical Grants Wyeth Pharmaceuticals License to Develop Infectious Disease DNA Vaccines







Inovio Biomedical Corp. (AMEX: INO), a leader in enabling the
development of DNA vaccines using electroporation-based DNA delivery,
announced today that it has granted Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE), a worldwide non-exclusive license to its DNA delivery
technology for intramuscular applications of certain therapeutic DNA
vaccines. Under the terms of the agreement, Inovio will receive from
Wyeth a $4.5 million upfront license fee, annual license maintenance
fees, research support, and up to $60 million in payments based on
successful completion of clinical and regulatory milestones. Inovio
would exclusively supply Wyeth with electroporation devices for the
vaccines included in the license agreement and would receive royalties
on the sale of products covered by the license.


"We are pleased to add Wyeth to the list of corporate partners using our
enabling MedPulser® DNA
Delivery System to develop DNA vaccines for the treatment of
debilitating diseases caused by a variety of viruses,
stated Avtar Dhillon, MD, president and CEO of Inovio. We
believe this speaks to the enabling capabilities of our technology, the
breadth of our clinical experience as well as the strength of our DNA
electroporation patent estate. We remain committed to commercializing
our delivery technology with a top-tier vaccine company such as Wyeth as
we strive to build the worlds leading DNA
vaccine delivery franchise.


About Inovios DNA Delivery Technology


DNA vaccines have the potential to by-pass the numerous problems that
plague conventional vaccines. For example, DNA vaccines may be better in
stimulating cellular immunity necessary to fight chronic infection or
diseases such as cancer. Despite this promise, vaccination using DNA
plasmids alone, without enhanced delivery, has not been shown to reach
the threshold for clinical benefit.


Intramuscular delivery of DNA vaccines using Inovios
proprietary electroporation technology has been shown in primate studies
to boost the immune response by orders of magnitude over DNA plasmid
alone. Plasmid-based vaccines induced higher levels of antibodies and
T-cell responses when delivered via electroporation, suggesting the
potential to provide better protection from infectious diseases such as
HIV and hepatitis C.


About Inovio Biomedical Corporation


Inovio Biomedical Corporation is a late stage biomedical company focused
on a cancer ablation therapy and development of multiple DNA vaccines.
Inovio is commercializing its proprietary Selective Electrochemical
Tumor Ablation (SECTA) therapy and its delivery platform for gene-based
treatments.


SECTA is designed for local treatment of solid tumors, with selective
killing of cancer cells while preserving surrounding healthy tissue.
Inovio is moving its lead product, the MedPulser®,
through pre-marketing studies for head and neck cancer and skin cancers
in Europe, where it has CE Mark accreditation, a U.S. Phase III pivotal
study for head and neck cancer, and a Phase I trial for breast cancer.


Merck, Vical, University of Southampton and H. Lee Moffitt Cancer Center
are conducting phase I clinical studies of novel gene-based therapies
and DNA vaccines delivered using Inovio's electroporation-based
technology. Innogenetics and Pharmexa are conducting DNA vaccine
clinical studies using the companys recently
acquired DNAvax® technology. Inovio is a
leader in developing human therapeutic applications of electroporation
and DNA vaccination, with the industry's most extensive patent portfolio
covering in vivo electroporation. More information is available at www.inovio.com.


This press release contains certain forward-looking statements
relating to our plans to develop our electroporation drug and gene
delivery technology. Actual events or results may differ from our
expectations as a result of a number of factors, including the
uncertainties inherent in clinical trials and product development
programs (including, but not limited to, the fact that pre-clinical
results referenced in this release may not be indicative of results
achievable from testing in humans), the availability of funding to
support continuing research and studies in an effort to prove safety and
efficacy of Inovios technology as a delivery
mechanism, the availability or potential availability of alternative
therapies or treatments for the conditions targeted by Inovio or its
collaborators, including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that Inovio and its
collaborators hope to develop, evaluation of potential opportunities,
issues involving patents and whether they or licenses to them will
provide Inovio with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or
defensible or infringe or allegedly infringe on rights of others or can
withstand claims of invalidity and whether Inovio can finance or devote
other significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of our
technology by potential corporate or other partners or collaborators,
capital market conditions, and other factors set forth in the our Annual
Report on Form 10-K for the year ended December 31, 2005, our Form 10-Q
for the six months ended June 30, 2006, and other regulatory filings.
There can be no assurance that any product in our product pipeline will
be successfully developed or manufactured, or that final results of
clinical studies will be supportive of regulatory approvals required to
market licensed products.


Inovio Biomedical Corp. (AMEX: INO), a leader in enabling the
development of DNA vaccines using electroporation-based DNA delivery,
announced today that it has granted Wyeth Pharmaceuticals, a division
of Wyeth (NYSE: WYE), a worldwide non-exclusive license to its DNA
delivery technology for intramuscular applications of certain
therapeutic DNA vaccines. Under the terms of the agreement, Inovio
will receive from Wyeth a $4.5 million upfront license fee, annual
license maintenance fees, research support, and up to $60 million in
payments based on successful completion of clinical and regulatory
milestones. Inovio would exclusively supply Wyeth with electroporation
devices for the vaccines included in the license agreement and would
receive royalties on the sale of products covered by the license.

¶ "We are pleased to add Wyeth to the list of corporate partners
using our enabling MedPulser(R) DNA Delivery System to develop DNA
vaccines for the treatment of debilitating diseases caused by a
variety of viruses," stated Avtar Dhillon, MD, president and CEO of
Inovio. "We believe this speaks to the enabling capabilities of our
technology, the breadth of our clinical experience as well as the
strength of our DNA electroporation patent estate. We remain committed
to commercializing our delivery technology with a top-tier vaccine
company such as Wyeth as we strive to build the world's leading DNA
vaccine delivery franchise."

¶ About Inovio's DNA Delivery Technology

¶ DNA vaccines have the potential to by-pass the numerous problems
that plague conventional vaccines. For example, DNA vaccines may be
better in stimulating cellular immunity necessary to fight chronic
infection or diseases such as cancer. Despite this promise,
vaccination using DNA plasmids alone, without enhanced delivery, has
not been shown to reach the threshold for clinical benefit.

¶ Intramuscular delivery of DNA vaccines using Inovio's proprietary
electroporation technology has been shown in primate studies to boost
the immune response by orders of magnitude over DNA plasmid alone.
Plasmid-based vaccines induced higher levels of antibodies and T-cell
responses when delivered via electroporation, suggesting the potential
to provide better protection from infectious diseases such as HIV and
hepatitis C.

¶ About Inovio Biomedical Corporation

¶ Inovio Biomedical Corporation is a late stage biomedical company
focused on a cancer ablation therapy and development of multiple DNA
vaccines. Inovio is commercializing its proprietary Selective
Electrochemical Tumor Ablation (SECTA) therapy and its delivery
platform for gene-based treatments.

¶ SECTA is designed for local treatment of solid tumors, with
selective killing of cancer cells while preserving surrounding healthy
tissue. Inovio is moving its lead product, the MedPulser(R), through
pre-marketing studies for head and neck cancer and skin cancers in
Europe, where it has CE Mark accreditation, a U.S. Phase III pivotal
study for head and neck cancer, and a Phase I trial for breast cancer.

¶ Merck, Vical, University of Southampton and H. Lee Moffitt Cancer
Center are conducting phase I clinical studies of novel gene-based
therapies and DNA vaccines delivered using Inovio's
electroporation-based technology. Innogenetics and Pharmexa are
conducting DNA vaccine clinical studies using the company's recently
acquired DNAvax(R) technology. Inovio is a leader in developing human
therapeutic applications of electroporation and DNA vaccination, with
the industry's most extensive patent portfolio covering in vivo
electroporation. More information is available at www.inovio.com.

¶ This press release contains certain forward-looking statements
relating to our plans to develop our electroporation drug and gene
delivery technology. Actual events or results may differ from our
expectations as a result of a number of factors, including the
uncertainties inherent in clinical trials and product development
programs (including, but not limited to, the fact that pre-clinical
results referenced in this release may not be indicative of results
achievable from testing in humans), the availability of funding to
support continuing research and studies in an effort to prove safety
and efficacy of Inovio's technology as a delivery mechanism, the
availability or potential availability of alternative therapies or
treatments for the conditions targeted by Inovio or its collaborators,
including alternatives that may be more efficacious or cost-effective
than any therapy or treatment that Inovio and its collaborators hope
to develop, evaluation of potential opportunities, issues involving
patents and whether they or licenses to them will provide Inovio with
meaningful protection from others using the covered technologies,
whether such proprietary rights are enforceable or defensible or
infringe or allegedly infringe on rights of others or can withstand
claims of invalidity and whether Inovio can finance or devote other
significant resources that may be necessary to prosecute, protect or
defend them, the level of corporate expenditures, assessments of our
technology by potential corporate or other partners or collaborators,
capital market conditions, and other factors set forth in the our
Annual Report on Form 10-K for the year ended December 31, 2005, our
Form 10-Q for the six months ended June 30, 2006, and other regulatory
filings. There can be no assurance that any product in our product
pipeline will be successfully developed or manufactured, or that final
results of clinical studies will be supportive of regulatory approvals
required to market licensed products.

Cheers
swseun

erx.. your missing out, OSI pharma just doing there webcast... in favour ERX as well ;-), all we need now is ERX to confirm

any idea when? :-) I am pointing my fingers.. to buy or later.....

bloody soon mate